Please assess the completion status of the following clinical trial:

Trial Title: PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of plexiform neurofibroma which is progressive, symptomatic, or life threatening and for which there is no other standard medical management or surgical option~* Histologic confirmation of tumor is not required in the presence of consistent clinical and radiographic findings provided the following are true:~  * No clinical observation or scan suggestive of malignant transformation~ * Meets ≥ 1 of the following diagnostic criteria for neurofibroma type 1 (NF1):~    * Six or more cafe-au-lait spots (\> 0.5 cm in prepubertal patients or \> 1.5 cm in post pubertal patients)~   * Freckling in axilla or groin~   * Optic glioma~   * Two or more Lisch nodules~   * A distinctive bony lesion (e.g., dysplasia of the sphenoid bone, dysplasia, or thinning of long bone cortex)~   * A first degree relative with NF1~* No history of malignant peripheral nerve sheath tumor~* No active visual pathway glioma~* No active brain tumor or brain metastases~PATIENT CHARACTERISTICS:~Performance status~* ECOG 0-2~Life expectancy~* At least 12 months~Hematopoietic~* Absolute neutrophil count \> 1,500/mm\^3~* Hemoglobin \> 10 g/dL~* Platelet count \> 100,000/mm\^3~Hepatic~* Bilirubin \< 1.5 mg/dL~* SGPT ≤ 2 times upper limit of normal~* No significant hepatic dysfunction~Renal~* Creatinine based on age as follows:~  * ≤ 0.8 mg/dL (for patients age 5 years and under)~ * ≤ 1.0 mg/dL (for patients age 6 to 10 years)~ * ≤ 1.2 mg/dL (for patients age 11 to 15 years)~ * ≤ 1.5 mg/dL (for patients age 16 to 21 years) OR~* Creatinine clearance ≥ 70 mL/min~Cardiovascular~* No significant cardiac dysfunction~* No severe cardiovascular disease~* No cardiac arrhythmia requiring chronic treatment~* No congestive heart failure~* No symptomatic ischemic heart disease~Pulmonary~* No significant pulmonary dysfunction~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No serious infection~* No other significant unrelated systemic illness~* No significant organ dysfunction~* No other malignancy except surgically cured nonmelanoma skin cancer or carcinoma in situ of the cervix~* No history of severe psychiatric condition or psychiatric disorder requiring hospitalization~* No history of suicidal ideation or attempt~* No thyroid dysfunction unresponsive to therapy~* No uncontrolled diabetes mellitus~* No history of HIV positivity~* No alcohol or drug abuse~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent immunotherapy~* No concurrent colony-stimulating factors (e.g., erythropoietin or filgrastim \[G-CSF\])~Chemotherapy~* No concurrent chemotherapy for this disease~Endocrine therapy~* No concurrent chronic systemic corticosteroids~* No concurrent hormonal therapy for this disease~Radiotherapy~* No concurrent radiotherapy for this disease~Surgery~* Prior surgery allowed provided it has been at least 21 days since surgery and there is presence of residual tumor~Other~* Recovered from prior therapy~* More than 30 days since prior investigational agents

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete